Jamesi Novum

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jamesi Novum, is a Biguanide/DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels. It is commonly prescribed as part of a comprehensive diabetes management plan.

GNH USA supplies Jamesi Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Jamesi Novum is a fixed‑dose combination that targets hyperglycaemia in type 2 diabetes mellitus and is used as part of a broader therapeutic strategy.

- Type 2 diabetes mellitus: improves glycaemic control when used with diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect as add‑on therapy. - Combination therapy with other antidiabetics: enables a simplified regimen for patients requiring multiple agents.

Adverse reactions may occur with any antidiabetic therapy and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: increased stool frequency, usually transient. - Headache: mild tension‑type headache. - Upper respiratory tract infection: symptoms of common cold.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Renal impairment: worsening kidney function, especially in dehydration.

Patients should be evaluated for safety before initiating therapy.

- Renal function monitoring: assess creatinine clearance prior to start and periodically thereafter. - Hepatic assessment: avoid in patients with significant liver disease. - Heart failure caution: contraindicated in severe, unstable heart failure. - Contrast media use: discontinue metformin before iodinated contrast procedures. - Elderly dose consideration: start with lower dose and titrate cautiously. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Drug interaction potential varies with concomitant medications.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; hold metformin before and after exposure. - Insulin or sulfonylureas: heightened risk of hypoglycaemia. - Cimetidine: may raise metformin plasma concentrations. - Strong CYP3A4 inhibitors: can elevate sitagliptin levels. - Excessive alcohol: potentiates metformin‑related lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Beta‑blockers: can mask hypoglycaemia symptoms. - Glucocorticoids: may increase blood glucose, requiring dose adjustment. - Warfarin: occasional reports of altered INR, monitor coagulation status.